Horizon Therapeutics to acquire MedImmune Spinout Viela Bio in deal with equity value of $3.05 billion

Published on : February 1, 2021February 1, 2021 Published by : Alex Keown

During a conference call this morning, Horizon Therapeutics Chief Executive Officer Tim Walbery pointed to the depth of Viela’s research and development programs, the company’s understanding of common mechanisms of autoimmunity, and its strong legacy management from MedImmune as net positives for Horizon. During the call, Walbery said Viela is a “strong strategic fit” that will drive long-term and sustainable growth for Horizon.

Viela Bio’s Uplizna Granted FDA Approval As Company’s First Commercial Product

Published on : June 15, 2020June 26, 2020 Published by : Steven Surdez

Viela Bio’s Uplizna™ Granted FDA Approval As Company’s First Commercial Product Viela Bio’s Uplizna™ (inebilizumab-cdon), a treatment for adult patients with neuromyelitis optica spectrum disorder (NMOSD), was approved by the [….]

The Top Biotech Companies That are Hiring – June 2020

Published on : June 9, 2020June 10, 2020 Published by : Chris Frew

The Top Biotech Companies That are Hiring – June 2020 June 9, 2020 Despite the uncertainty created by the COVID-19 pandemic, companies across the BioHealth Capital Region (BHCR) continue to [….]

Industry Leaders Outline Best Strategies for Attracting Talent in the BioHealth Capital Region

Published on : April 21, 2020June 9, 2020 Published by : Steven Surdez

Industry Leaders Outline Best Strategies for Attracting Talent in the BioHealth Capital Region Recruiting and attracting talent is one of the top priorities and challenges for biotech and life science [….]

BioHealth Capital Region Startups Raised More Than $739M in 2019

Published on : December 17, 2019December 17, 2019 Published by : Chris Frew

BioHealth Capital Region Startups Raised More Than $739M in 2019 These 15 Biohealth Startups had a Banner Year, Setting Themselves Up for Success in 2020 The startup ecosystem in the [….]

Viela Bio Rings Nasdaq Opening Bell in Highly Anticipated Biotech IPO

Published on : October 3, 2019September 26, 2020 Published by : Chris Frew

Viela Bio Rings Nasdaq Opening Bell in Highly Anticipated Biotech IPO October 3, 2019 It has been just 20 months since Viela Bio was founded and today Viela Bio CEO [….]

Why Developing Cures for Rare Disease Isn’t So Rare Anymore

Published on : September 3, 2019September 5, 2019 Published by : Steven Surdez

Why Developing Cures for Rare Disease Isn’t So Rare Anymore These Six Maryland Biotech Companies Are Seeing Success in Targeting Rare Diseases September 3, 2019 Groundbreaking technology and scientific advancements, [….]

Viela Bio Becomes Latest Biotech Intent on Going Public with $150M Offering

Published on : August 30, 2019August 30, 2019 Published by : Chris Frew

Viela Bio Becomes Latest Biotech Intent on Going Public with $150M Offering AstraZeneca spinout files for IPO on Nasdaq August 29, 2019 Viela Bio, the AstraZeneca spin-off biotech, has captured [….]

Maryland Pavilion to Showcase State’s Thriving Biotech Community at Annual BIO Convention

Published on : May 28, 2019June 3, 2019 Published by : Steven Surdez

BIO 2019 Maryland Pavilion

Viela Bio Receives U.S. FDA Breakthrough Therapy Designation for Inebilizumab for Treatment of Neuromyelitis Optica Spectrum Disorder

Published on : April 18, 2019September 26, 2020 Published by : Chris Frew

Viela Bio Receives U.S. FDA Breakthrough Therapy Designation for Inebilizumab for Treatment of Neuromyelitis Optica Spectrum Disorder Designation based on positive primary analysis of pivotal study, N-MOmentum Gaithersburg, MD—April 18, [….]